

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

DERMA SCIENCES, INC.
Form SC 13D/A
February 02, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

AMENDMENT NO. 9 TO
SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

DERMA SCIENCES, INC.

(Name of Issuer)

COMMON STOCK, \$.01 PAR VALUE PER SHARE

(Title of Class of Securities)

249827106

(CUSIP Number)

Bruce F. Wesson
Senior Managing Member
Claudius, L.L.C.
610 Fifth Avenue, 5th Floor
New York, NY 10020
(212) 218-4990

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

JANUARY 31, 2005

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box :.

Note: Schedules filed in paper format shall include a signed original and five copies with the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all provisions of the Act (however, see the Notes).

Page 1 of 9 Pages

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

Securities and Exchange Commission ("SEC") on February 6, 1998 for an event on January 23, 1998, and subsequently amended on September 18, 1998 by Amendment No. 1, and on August 24, 1999 by Amendment No.2, and on January 10, 2000 by Amendment No. 3, and on August 7, 2000 by Amendment No. 4, and on March 19, 2001 by Amendment No. 5, and on March 16, 2002 by Amendment No. 6, and on May 16, 2003 by Amendment No. 7, and on June 23, 2003 by Amendment No. 8, is hereby further amended to read as follows:

SCHEDULE 13D

CUSIP No. 249827106

PAGE 2 of 9 PAGES

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Galen Partners III, L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC USE ONLY	
4	SOURCE OF FUNDS WC	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) or 2(E)	<input type="checkbox"/>
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
7	SOLE VOTING POWER 4,890,201 (see Item 5(a))	
8	SHARED VOTING POWER 0	
9	SOLE DISPOSITIVE POWER 4,890,201	
10	SHARED DISPOSITIVE POWER 0	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY THE REPORTING PERSON 4,890,201	
12	CHECK BOX IF THE AGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	<input type="checkbox"/>
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 35.4%	
14	TYPE OF REPORTING PERSON PN	

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

Page 3 of 9 of the Schedule 13D, as amended, is hereby further amended to read in its entirety as follows:

SCHEDULE 13D

CUSIP No. 249827106

PAGE 3 of 9 PAGES

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Galen Partners International III, L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC USE ONLY	
4	SOURCE OF FUNDS WC	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) or 2(E)	<input type="checkbox"/>
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
	7 SOLE VOTING POWER 442,995 (see Item 5(a))	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8 SHARED VOTING POWER 0	
	9 SOLE DISPOSITIVE POWER 442,995	
	10 SHARED DISPOSITIVE POWER 0	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY THE REPORTING PERSON 442,995	
12	CHECK BOX IF THE AGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	<input type="checkbox"/>
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.2%	
14	TYPE OF REPORTING PERSON PN	

Page 4 of 9 of the Schedule 13D, as amended, is hereby further amended to read in its entirety as follows:

SCHEDULE 13D

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

CUSIP No. 249827106

PAGE 4 of 9 PAGES

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Galen Employee Fund III, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS
WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEM 2(D) or 2(E)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 20,044 (see Item 5(a))
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 20,044
	10	SHARED DISPOSITIVE POWER 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY THE REPORTING PERSON
20,044

12 CHECK BOX IF THE AGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.15%

14 TYPE OF REPORTING PERSON
PN

4

Page 5 of 9 of the Schedule 13D, as amended, is hereby further amended to read in its entirety as follows:

SCHEDULE 13D

CUSIP No. 249827106

PAGE 5 of 9 PAGES

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
William R. Grant

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a) <input type="checkbox"/>
	(b) <input checked="" type="checkbox"/>

3	SEC USE ONLY

4	SOURCE OF FUNDS
	PF

5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) or 2(E)
	<input type="checkbox"/>

6	CITIZENSHIP OR PLACE OF ORGANIZATION

	7 SOLE VOTING POWER
NUMBER OF	774,500 (see Item 5(a))
SHARES	-----
BENEFICIALLY	8 SHARED VOTING POWER
OWNED BY	0
EACH	-----
REPORTING	9 SOLE DISPOSITIVE POWER
PERSON WITH	774,500

	10 SHARED DISPOSITIVE POWER
	0

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY THE REPORTING PERSON
	774,500

12	CHECK BOX IF THE AGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
	<input type="checkbox"/>

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	5.6%

14	TYPE OF REPORTING PERSON
	IN

5

The first paragraph of Item 1 of the Schedule 13D is hereby amended to read in its entirety as follows:

"This statement covers a total of 6,127,740 fully diluted shares of Common Stock, \$.01 par value per share (the "Common Stock"), of Derma Sciences, Inc., a Pennsylvania corporation (the "Issuer"). The Reporting Persons (as defined in Item 2 hereof) as of the date hereof hold an aggregate of (i) 1,936,500 shares of Common Stock, (ii) 543,267 shares of Series B Convertible Preferred Stock, \$.01 par value per share, of the Issuer (the "Series B Preferred Shares"), which as of the date hereof are convertible into an aggregate of 543,267 shares of Common Stock, (iii) 617,184 shares of Series C Convertible Preferred Stock, \$.01 par value

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

per share, of the Issuer (the "Series C Preferred Shares"), which as of the date hereof are convertible into an aggregate of 617,184 shares of Common Stock, (iv) 1,071,345 shares of Series D Convertible Preferred Stock, \$.01 par value per share, of the Issuer (the "Series D Preferred Shares"), which as of the date hereof are convertible into an aggregate of 1,071,345 shares of Common Stock, and (v) 1,959,444 warrants (the "Warrants"), which as of the date hereof may be exercised for an aggregate of 1,959,444 shares of Common Stock. The Common Stock, Series B Preferred Shares, Series C Preferred Shares, Series D Preferred Shares and Warrants are referred to herein, collectively, as the "Securities".

The third paragraph of Item 3 of the Initial Schedule 13D is hereby amended to read in its entirety as follows:

"William R. Grant, a Reporting Person, acquired in a private transaction with the Issuer on January 31, 2005, 100,000 units at a purchase price of \$0.50 per unit for an aggregate amount of \$50,000 in cash. The units consist of 100,000 shares of Common Stock and warrants to purchase an additional 100,000 shares of Common Stock."

6

Item 5, subpart (a) of the Initial Schedule 13D is hereby amended to read in its entirety as follows:

(a) Each Reporting Person owns or has the right to acquire the number of securities shown opposite its name:

(1)	(2)	(3)	(4)	(5)
Reporting Person	Number of Shares of Common Stock	Number of Shares of Common Stock into which Series B, Series C and Series D Preferred Stock is Convertible	Number of Shares of Common Stock which may be acquired pursuant to exercise of Warrants	Total of Columns (2), (3) and (4)
Galen	1,152,611	2,038,869	1,698,721	4,890,201
Galen Intl	104,654	184,577	153,764	442,995
GEF	4,735	8,350	6,959	20,044
Grant	674,500	0	100,000	774,500
Total	1,936,500	2,231,796	1,959,444	6,127,740

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

Note: The percentages shown in each row of column (6) were calculated, for each respective row, by (i) adding the total in the bottom rows of columns (3) and (4) to 9,624,007 (the number of shares of Common Stock outstanding as of September 30, 2004, as set forth in the Issuer's Quarterly Report on Form 10-QSB for the quarter then ended, plus the 100,000 shares of Common Stock acquired by William R. Grant as reported herein (the "Total Adjusted Outstanding Shares"), then (ii) dividing the amount in column (5) by the Total Adjusted Outstanding Shares, and then (iii) expressing such quotient in terms of a percentage.

7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in the statement is true, complete and correct.

Date: February 2, 2005

GALEN PARTNERS III, L.P.

By: Claudius, L.L.C.

By: /s/ Bruce F. Wesson

Managing Member

GALEN PARTNERS

INTERNATIONAL III, L.P.

By: Claudius, L.L.C

By: /s/ Bruce F. Wesson

Managing Member

GALEN EMPLOYEE FUND III, L.P.

By: Wesson Enterprises, Inc

By: /s/ Bruce F. Wesson

President

[Signatures continued on next page.]

8

CLAUDIUS, L.L.C.

By: /s/ Bruce F. Wesson

Managing Member

WESSON ENTERPRISES, INC.

Edgar Filing: DERMA SCIENCES, INC. - Form SC 13D/A

By: /s/ Bruce F. Wesson

President

WILLIAM R. GRANT

By: /s/ Bruce F. Wesson

Bruce F. Wesson, Attorney-In-Fact

BRUCE F. WESSON

/s/ Bruce F. Wesson

Bruce F. Wesson

L. JOHN WILKERSON

By: /s/ Bruce F. Wesson

Bruce F. Wesson, Attorney-In-Fact

DAVID JAHNS

By: /s/ Bruce F. Wesson

Bruce F. Wesson, Attorney-In-Fact

SRINI CONJEEVARAM

By: /s/ Bruce F. Wesson

Bruce F. Wesson, Attorney-In-Fact

ZUBEEN SHROFF

By: /s/ Bruce F. Wesson

Bruce F. Wesson, Attorney-In-Fact